Core Laboratories NV (NYSE:CLB) – DA Davidson issued their Q3 2016 earnings estimates for shares of Core Laboratories NV in a report released on Wednesday. DA Davidson analyst S. Randhawa anticipates that the brokerage will post earnings of $0.39 per share for the quarter. DA Davidson has a “Buy” rating and a $136.00 price objective on the stock. DA Davidson also issued estimates for Core Laboratories NV’s Q4 2016 earnings at $0.43 EPS, FY2016 earnings at $1.54 EPS, Q1 2017 earnings at $0.50 EPS, Q2 2017 earnings at $0.54 EPS, Q3 2017 earnings at $0.66 EPS, Q4 2017 earnings at $0.76 EPS and FY2017 earnings at $2.46 EPS.

Core Laboratories NV (NYSE:CLB) last released its quarterly earnings data on Wednesday, July 20th. The company reported $0.35 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.35. Core Laboratories NV had a net margin of 11.81% and a return on equity of 344.55%. The firm had revenue of $148.10 million for the quarter, compared to the consensus estimate of $146.37 million. During the same period in the previous year, the company earned $0.81 earnings per share. The company’s quarterly revenue was down 27.4% on a year-over-year basis.

Earnings History and Estimates for Core Laboratories NV (NYSE:CLB)

Several other brokerages also recently commented on CLB. Zacks Investment Research raised shares of Core Laboratories NV from a “sell” rating to a “hold” rating in a research report on Thursday, October 6th. Citigroup Inc. cut their target price on Core Laboratories NV from $118.00 to $116.00 and set a “neutral” rating on the stock in a report on Monday, September 12th. Credit Suisse Group AG began coverage on Core Laboratories NV in a report on Thursday, September 1st. They issued a “neutral” rating and a $115.00 target price on the stock. Loop Capital began coverage on Core Laboratories NV in a report on Friday, September 30th. They issued a “hold” rating and a $120.00 target price on the stock. Finally, JPMorgan Chase & Co. cut Core Laboratories NV from a “neutral” rating to an “underweight” rating in a report on Tuesday, July 12th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $121.61.

Core Laboratories NV (NYSE:CLB) opened at 114.42 on Monday. The firm has a market capitalization of $5.05 billion, a P/E ratio of 60.70 and a beta of 1.45. Core Laboratories NV has a 12-month low of $84.50 and a 12-month high of $135.49. The firm has a 50 day moving average of $111.04 and a 200 day moving average of $117.55.

A number of large investors have recently made changes to their positions in CLB. Ranger Investment Management L.P. raised its stake in shares of Core Laboratories NV by 0.8% in the second quarter. Ranger Investment Management L.P. now owns 2,565 shares of the company’s stock valued at $318,000 after buying an additional 20 shares during the period. Montag & Caldwell LLC raised its stake in shares of Core Laboratories NV by 0.7% in the second quarter. Montag & Caldwell LLC now owns 4,450 shares of the company’s stock valued at $551,000 after buying an additional 30 shares during the period. BlackRock Investment Management LLC raised its stake in shares of Core Laboratories NV by 1.4% in the second quarter. BlackRock Investment Management LLC now owns 4,915 shares of the company’s stock valued at $609,000 after buying an additional 68 shares during the period. Parsons Capital Management Inc. RI raised its stake in shares of Core Laboratories NV by 3.6% in the second quarter. Parsons Capital Management Inc. RI now owns 2,150 shares of the company’s stock valued at $266,000 after buying an additional 75 shares during the period. Finally, Laurel Wealth Advisors Inc. raised its stake in shares of Core Laboratories NV by 3.6% in the second quarter. Laurel Wealth Advisors Inc. now owns 2,132 shares of the company’s stock valued at $264,000 after buying an additional 75 shares during the period.

About Core Laboratories NV

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

5 Day Chart for NYSE:CLB

Receive News & Stock Ratings for Core Laboratories NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories NV and related stocks with our FREE daily email newsletter.